Live Q&A: The Team, The Team, The Team: Creating a Short Bowel Syndrome Medical Neighborhood
Premiere Date: Wednesday, August 3, 2022This activity offers CE credit for:
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, August 3, 2023
Note: Credit Is No Longer Available
 | Miguel Regueiro, MD, AGAF, FACG, FACP (Moderator) Chair, Digestive Disease and Surgery Chair, Department of Gastroenterology, Hepatology, and Nutrition The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology Professor, Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, OH |
 | Kishore R. Iyer, MBBS, FRCS (Eng), FACS Director, Intestinal Rehab & Transplant Program Program Director, Transplant Surgery Fellowship Professor of Surgery & Pediatrics Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai New York, NY |
 | Donald F. Kirby, MD, FACP, FACN, FACG, AGAF, FASPEN, CNSC, CPNS Director, Center for Human Nutrition Medical Director, Intestinal Transplant Program Professor of Medicine Cleveland Clinic Cleveland, OH |
Although short bowel syndrome (SBS) remains a relatively rare disorder, the number of cases has doubled in the past 40 years. Due to this increased disease incidence and a projected shortage of gastroenterologists, an interdisciplinary approach is needed inclusive of primary care physicians, PAs, and nurse practitioners who are likely to be recruited to care for this patient population.
This live question and answer session is your opportunity to ask questions based on the CME Outfitters Live and OnDemand activity where expert faculty focused on integrating an interdisciplinary team to optimize the management of patients with SBS, with a focus on applying efficacy and safety data to treatment decision-making and implementing best practices from state-of-the-art intestinal rehabilitation centers in the community to improve access and care. To view the full activity ahead of this live Q&A, Click Here.
At the end of this CE activity, participants should be able to:
- Integrate an interdisciplinary team to optimize the management of patients with SBS.
- Apply efficacy and safety data to treatment decision-making for patients with SBS.
- Implement best practices from state-of-the-art SBS/IR centers in the community to improve access and care for patients with SBS.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, surgeons, pediatricians, internists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists, social workers, dietitians, psychologists, and feeding therapists
IPCE:
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Alfasigma, S.p.A.; Allergan; Amgen Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Miraca Laboratories; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc.; and UCB, Inc.
Research Support: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Royalties: Wolters Kluwer Health as Author/Editor of UpToDate
Unrestricted Educational Grants: AbbVie Inc.; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Iyer reports the following financial relationships:
Consultant: Hanmi Pharmaceutical, Co., Ltd.; Ipsen Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and VectivBio
Grants: Takeda Pharmaceuticals U.S.A.
Research Support: Takeda Pharmaceuticals U.S.A.; VectivBio; and Zealand Pharma A/S
Dr. Kirby reports the following financial relationships:
Advisory Board: OWYN, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and VectivBio
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TVQ-129-080322-20
